Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.

First-quarter revenue rose 19% year-over-year, bolstered by a 21% increase in sales of diabetes and obesity care products. Wegovy, a key GLP-1 therapy, posted an 83% surge in global sales, while U ...

Novo Nordisk AS (NYSE:NVO) reported an 18% sales growth and 20% operating profit growth in the first quarter of 2025. The company is serving nearly 46 million patients with diabetes and obesity ...

Novo Nordisk stock reported strong sales growth but lowered sales forecasts this morning. The good news: 2025 earnings will grow faster than sales. Novo Nordisk reports its results in Danish ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk reported constant currency sales growth of 18% in the first quarter and lowered the midpoint of its 2025 constant currency sales growth guidance from 20% to 17%. As it reports in ...